Table 2 Clinical and pathological features of patients newly diagnosed as infiltrating duct carcinoma with bone metastasis
Variables | Total cohort | Training cohort | Validation cohort | |||
|---|---|---|---|---|---|---|
N = 2383 | N = 1671 | N = 712 | ||||
n | % | n | % | n | % | |
Age | ||||||
 22–54 | 851 | 35.71 | 596 | 35.67 | 255 | 35.81 |
 55–79 | 1294 | 54.30 | 901 | 53.92 | 393 | 55.20 |
 ≥ 80 | 238 | 9.99 | 174 | 10.41 | 64 | 8.99 |
Race | ||||||
 Black | 317 | 13.30 | 228 | 13.65 | 89 | 12.50 |
 Other | 187 | 7.85 | 123 | 7.36 | 64 | 8.99 |
 White | 1879 | 78.85 | 1320 | 78.99 | 559 | 78.51 |
Sex | ||||||
 Female | 2341 | 98.24 | 1638 | 98.03 | 703 | 98.74 |
 Male | 42 | 1.76 | 33 | 1.97 | 9 | 1.26 |
Primary Site | ||||||
 Nipple | 13 | 0.55 | 12 | 0.72 | 1 | 0.14 |
 Central portion of breast | 223 | 9.36 | 163 | 9.75 | 60 | 8.43 |
 Upper-inner quadrant of breast | 229 | 9.61 | 170 | 10.17 | 59 | 8.29 |
 Lower-inner quadrant of breast | 156 | 6.55 | 112 | 6.70 | 44 | 6.18 |
 Upper-outer quadrant of breast | 865 | 36.30 | 603 | 36.09 | 262 | 36.80 |
 Lower-outer quadrant of breast | 184 | 7.72 | 133 | 7.96 | 51 | 7.16 |
 Axillary tail of breast | 19 | 0.80 | 10 | 0.60 | 9 | 1.26 |
 Overlapping lesion of breast | 694 | 29.12 | 468 | 28.01 | 226 | 31.74 |
Grade | ||||||
 I | 156 | 6.55 | 106 | 6.34 | 50 | 7.02 |
 II | 1104 | 46.33 | 785 | 46.98 | 319 | 44.80 |
 III | 1118 | 46.91 | 777 | 46.50 | 341 | 47.90 |
 IV | 5 | 0.21 | 3 | 0.18 | 2 | 0.28 |
Laterality | ||||||
 Left - origin of primary | 1247 | 52.33 | 869 | 52.00 | 378 | 53.09 |
 Right - origin of primary | 1136 | 47.67 | 802 | 48.00 | 334 | 46.91 |
T stage | ||||||
 T1 | 336 | 14.10 | 253 | 15.14 | 83 | 11.66 |
 T2 | 987 | 41.42 | 670 | 40.10 | 317 | 44.52 |
 T3 | 405 | 16.99 | 291 | 17.41 | 114 | 16.01 |
 T4 | 655 | 27.49 | 457 | 27.35 | 198 | 27.81 |
N stage | ||||||
 N0 | 557 | 23.37 | 380 | 22.74 | 177 | 24.86 |
 N1 | 1160 | 48.68 | 820 | 49.07 | 340 | 47.75 |
 N2 | 321 | 13.47 | 225 | 13.47 | 96 | 13.48 |
 N3 | 345 | 14.48 | 246 | 14.72 | 99 | 13.91 |
Radiotherapy | ||||||
 No | 1782 | 74.78 | 1239 | 74.15 | 543 | 76.26 |
 Yes | 601 | 25.22 | 432 | 25.85 | 169 | 23.74 |
Chemotherapy | ||||||
 No | 976 | 40.96 | 688 | 41.17 | 288 | 40.45 |
 Yes | 1407 | 59.04 | 983 | 58.83 | 424 | 59.55 |
Surgery | ||||||
 No | 1465 | 61.48 | 1018 | 60.92 | 447 | 62.78 |
 Yes | 918 | 38.52 | 653 | 39.08 | 265 | 37.22 |
Brain metastasis | ||||||
 No | 2260 | 94.84 | 1582 | 94.67 | 678 | 95.22 |
 Yes | 123 | 5.16 | 89 | 5.33 | 34 | 4.78 |
Liver metastasis | ||||||
 No | 1881 | 78.93 | 1338 | 80.07 | 543 | 76.26 |
 Yes | 502 | 21.07 | 333 | 19.93 | 169 | 23.74 |
Lung metastasis | ||||||
 No | 1811 | 76.00 | 1258 | 75.28 | 553 | 77.67 |
 Yes | 572 | 24.00 | 413 | 24.72 | 159 | 22.33 |
Breast subtype | ||||||
 HR−/HER2- | 238 | 9.99 | 168 | 10.05 | 70 | 9.83 |
 HR−/HER2+ | 167 | 7.01 | 116 | 6.94 | 51 | 7.16 |
 HR+/HER2- | 1525 | 63.99 | 1091 | 65.29 | 434 | 60.96 |
 HR+/HER2+ | 453 | 19.01 | 296 | 17.72 | 157 | 22.05 |
HER2 status | ||||||
 Negative | 1763 | 73.98 | 1259 | 75.34 | 504 | 70.79 |
 Positive | 620 | 26.02 | 412 | 24.66 | 208 | 29.21 |
Insurance | ||||||
 Uninsured | 126 | 5.29 | 90 | 5.39 | 36 | 5.06 |
 Insured | 2257 | 94.71 | 1581 | 94.61 | 676 | 94.94 |
Marital status | ||||||
 Unmarried | 1101 | 46.20 | 760 | 45.48 | 341 | 47.89 |
 Married | 1282 | 53.80 | 911 | 54.52 | 371 | 52.11 |